Patent: 7,632,490
✉ Email this page to a colleague
Summary for Patent: 7,632,490
Title: | Use of IL-1 antagonists to treat gout |
Abstract: | Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. |
Inventor(s): | Vicary; Catherine (New York, NY), Mellis; Scott (New Rochelle, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 12/200,681 |
Patent Claims: | see list of patent claims |
Details for Patent 7,632,490
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | ELITEK | rasburicase | For Injection | 103946 | 07/12/2002 | ⤷ Try a Trial | 2039-02-26 |
Sanofi-aventis U.s. Llc | ELITEK | rasburicase | For Injection | 103946 | 01/06/2006 | ⤷ Try a Trial | 2039-02-26 |
Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | 02/27/2008 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |